Potassium-Chloride is the generic equivalent to KV Pharmaceutical’s Micro-K Extencaps USP and is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis.
Watson plans to launch its Potassium Chloride extended-release product during the third quarter of 2008. The specific launch date will depend upon the timing of product validation activities and manufacturing of launch.